

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

CD45RA

RRID:AB_1727496

Type: Antibody

Proper Citation

BD Biosciences Cat# 560673, RRID:AB_1727496

Antibody Information

URL: http://antibodyregistry.org/AB_1727496

Proper Citation: BD Biosciences Cat# 560673, RRID:AB_1727496

Target Antigen: CD45RA

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD45RA

Description: This monoclonal targets CD45RA

Target Organism: human

Antibody ID: AB_1727496

Vendor: BD Biosciences

Catalog Number: 560673

Record Creation Time: 20231110T073011+0000

Record Last Update: 20260830T004524+0000

Ratings and Alerts

No rating or validation information has been found for CD45RA.

No alerts have been found for CD45RA.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gardam B, et al. (2026) Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor. *iScience*, 29(3), 115160.

Roostaei T, et al. (2026) Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis. *Cell reports*, 45(6), 117417.

Moro A, et al. (2025) Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming. *iScience*, 28(6), 112553.

Lee H, et al. (2025) TCR signaling via NFATc1 constrains IL-15-induced bystander activation of human memory CD8+ T cells. *Immunity*, 58(12), 2957.

Jeon SH, et al. (2025) Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4586.

Cui T, et al. (2024) Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting. *EBioMedicine*, 99, 104903.

Liechti T, et al. (2023) A robust pipeline for high-content, high-throughput immunophenotyping reveals age- and genetics-dependent changes in blood leukocytes. *Cell reports methods*, 3(10), 100619.

Ettinger RA, et al. (2023) Technical Validation and Utility of an HLA Class II Tetramer Assay for Type 1 Diabetes: A Multicenter Study. *The Journal of clinical endocrinology and metabolism*, 109(1), 183.

Gantner P, et al. (2023) HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections. *Immunity*, 56(3), 653.

Wang X, et al. (2023) CD70-induced differentiation of proinflammatory Th1/17/22/GM lymphocytes associated with disease progression and immune reconstitution during HIV infection. *Emerging microbes & infections*, 12(2), 2271068.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. *Cell reports methods*, 3(1), 100388.

Falquet M, et al. (2023) Dynamic single-cell regulomes characterize human peripheral blood innate lymphoid cell subpopulations. *iScience*, 26(9), 107728.

Law H, et al. (2022) Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response. *iScience*, 25(1), 103656.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Olson KE, et al. (2021) Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. *EBioMedicine*, 67, 103380.

Vanoni G, et al. (2021) Human primed ILCPs support endothelial activation through NF- κ B signaling. *eLife*, 10.

Krummey SM, et al. (2020) CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence. *Cell reports*, 30(5), 1282.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. *Cell reports. Medicine*, 1(8), 100141.

Swadling L, et al. (2020) Human Liver Memory CD8+ T Cells Use Autophagy for Tissue Residence. *Cell reports*, 30(3), 687.